id: 111, Created by Stan Vick, Scout
Ampio (AMPE) Shareholder Settlement
How it works?
- Company agreed to settle with investors to avoid further litigation
- We prepare documents and claim payout for you
29 Dec 2020Class period Start
03 Aug 2022Class period End
Ampio (AMPE) agreed in principle to settle with investors to end claims over misrepresenting the efficacy of Ampion in treating individuals with inflammatory conditions.
In 2022, Ampio (AMPE) issued a letter to Shareholders covering the initial results of the investigation initiated on May 16, 2022.
- Special Committee's primary findings include that certain former Ampio executive officers and senior staff were aware, at the time of the per-protocol interim analysis in March 2020, that the AP-013 trial did not demonstrate efficacy for Ampion on its co-primary endpoints of pain and function;
- These former Ampio executive officers and senior staff did not fully report the results of the AP-013 trial and the timing of unblinding of data from the AP-013 trial.
Failure to Disclose,
Payout per Share
17 August 2022
Lead Plaintiff Deadline
17 October 2022
Tao Wang, Christopher Kain
Faruqi & Faruqi LLP (New York, NY)
Michael A. Martino, Michael Macaluso, Holli Cherevka, Dan Stokely, David Bar-Or, Philip H. Coelho, Richard B. Giles
Hon. William J. Martinez
Trades matching type